

Reference Data

Fiscal Year 2021
(April 1, 2021 to March 31, 2022)

Consolidated Earnings

• Consolidated Financial Data	p. 1
• Consolidated Balance Sheets	p. 2
• Consolidated P/L Statement	p. 3
• Consolidated Sales Breakdown by Segment/Category	p. 4
• Consolidated Operating Profit by Segment	p. 4
• Consolidated Sales - Leading Brands of Self-Medication Operations	
Sales by Region	p. 5
• Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations	p. 6
• Capital Expenditure	p. 7
• Depreciation and Amortization	p. 7
• R&D Expenses	p. 7
• Major Subsidiaries and Affiliates	p. 8
• Shareholders Information	p. 9
• Prescription Pharmaceutical Operations: New Drug Development-Taisho Pharmaceutical	p. 10
• Status of New Products	p. 12

Taisho Pharmaceutical Holdings Co.,Ltd.

Consolidated Financial Data

(Millions of yen)

	March 2019 (FY2018)	March 2020 ³ (FY2019)	March 2021 (FY2020)	March 2022 (FY2021)	(Est) March 2023 Full year
Net sales	244,039	273,178	267,920	268,203	280,500
(YOY%)	(-6.8%)	(+11.9%)	(-1.9%)	(+0.1%)	(+4.6%)
Self-Medication operations	169,088	209,806	217,056	229,659	243,600
Prescription Pharmaceutical operations	74,950	63,371	50,863	38,543	36,900
Gross profit on sales ^{*1}	153,281	165,950	163,815	163,831	173,100
Selling, general and administrative expenses	122,069	144,813	143,849	153,088	157,100
Research and development expenses (% Sales)	20,801 (8.5%)	22,876 (8.4%)	20,251 (7.6%)	19,366 (7.2%)	22,600 (8.1%)
Advertising expenses	20,206	26,046	25,017	31,898	30,000
Sales promotion expenses	13,338	16,275	15,255	14,438	16,300
Personnel expenses	32,491	31,017	32,953	34,128	34,800
Operating Profit	31,211	21,137	19,965	10,743	16,000
(YOY%)	(-15.6%)	(-32.3%)	(-5.5%)	(-46.2%)	(+48.9%)
Earnings before the amortization of goodwill and trademarks	35,201	29,470	32,008	23,162	28,100
Ordinary Profit	40,851	24,474	25,946	18,412	20,000
(YOY%)	(-3.1%)	(-40.1%)	(+6.0%)	(-29.0%)	(+8.6%)
Profit attributable to owners of parent	48,593	20,172	13,316	13,122	12,000
(YOY%)	(+53.4%)	(-58.5%)	(-34.0%)	(-1.5%)	(-8.6%)
Comprehensive income	48,027	8,470	28,920	21,162	-
(YOY%)	(+31.1%)	(-82.4%)	(+241.4%)	(-26.8%)	-
Basic EPS (yen)	608.80	252.74	166.84	161.12	146.26
Diluted EPS (yen)	608.22	252.44	166.63	160.93	146.08
BPS (yen)	8,924.23	8,887.84	9,129.95	9,116.28	9,164.83
Dividend per share (yen)	120.00	110.00	100.00	100.00	100.00
Payout ratio	19.7%	43.5%	59.9%	62.1%	68.4%
Capital expenditure	5,259	9,469	15,121	16,880	34,700
Depreciation and amortization	10,073	12,610	14,700	15,379	15,200
Total assets	821,782	864,974	876,923	888,159	892,000
Shareholders' equity	724,137	739,778	758,406	767,957	772,000
Return on equity (%) ^{*2}	7.0%	2.8%	1.9%	1.8%	1.6%
Return on assets (%) ^{*2}	6.0%	2.4%	1.5%	1.5%	1.4%
Equity ratio (%)	86.7%	82.0%	83.1%	84.2%	84.7%
Overseas sales	30,978	69,500	92,607	101,558	106,000
Overseas sales ratio (% of total sales)	12.7%	25.4%	32.8%	37.9%	37.8%
Number of employees	5,142	9,354	9,195	9,134	-

* Figures were obtained after application of the accounting standard for revenue recognition

*1 After provision for return adjustment and adjustment of return

*2 Average of the beginning and year-end balance of shareholders' equity / total assets

*3 Retroactive revisions to the fiscal year ended March 31, 2021 due to the determination of the allocation of acquisition costs associated with business combinations

Consolidated Balance Sheets

(Millions of yen)

(Millions of yen)

	End of FY2020		End of FY2021		change	
	(March 31, 21)	% total	(March 31, 22)	% total		
(Assets)						
I Current assets:	357,731	40.8%	378,864	42.7%	+21,133	
Cash and deposits	250,178		265,049		+14,870	
Notes and accounts receivable-trade	51,609		53,676		+2,067	
Marketable securities	4,017		7,219		+3,201	
Inventories	46,384		44,892		-1,492	
Other	5,540		8,027		+2,486	
II Fixed assets:	519,192	59.2%	509,294	57.3%	-9,897	
(1) Tangible fixed assets:	113,194	(12.9%)	119,291	(13.4%)	+6,097	
Buildings and structures	51,876		49,455		-2,421	
Machinery, equipment and vehicles	14,494		15,291		+797	
Land	37,429		37,394		-35	
Other	9,393		17,150		+7,757	
(2) Intangible fixed assets:	216,532	(24.7%)	213,059	(24.0%)	-3,473	
Goodwill	128,612		125,769		-2,842	
Sales rights	453		366		-86	
Trademarks	69,258		68,060		-1,198	
Software	10,341		10,812		+470	
Other	7,867		8,050		+183	
(3) Investments and other assets:	189,464	(21.6%)	176,943	(19.9%)	-12,521	
Investment securities	156,055		141,067		-14,987	
Shares of subsidiaries and affiliates	12,261		12,557		+295	
Net defined benefit assets	10,620		11,240		+619	
Deferred tax assets	8,892		9,508		+616	
Other	1,634		2,569		+934	
Total assets	876,923	100.0%	888,159	100.0%	+11,235	
(Liabilities)						
I Current liabilities:	57,666	6.6%	62,277	7.0%	+4,611	
Notes and accounts payable-trade	14,672		15,101		+429	
Accounts payable	16,068		15,521		-547	
Accrued income taxes	3,275		3,579		+304	
Refund liability	-		8,796		+8,796	
Provision for bonuses	3,523		3,633		+109	
Other	20,126		15,645		-4,480	
II Long-term liabilities:	60,849	6.9%	57,924	6.5%	-2,925	
Net defined benefit liabilities	21,321		21,329		+7	
Deferred taxes liabilities	32,747		29,162		-3,584	
Other	6,780		7,431		+650	
Total liabilities	118,516	13.5%	120,202	13.5%	+1,685	
(Net assets)						
I Shareholders' equity	697,598	79.6%	711,950	80.2%	+14,351	
Common stock	30,000		30,000		-	
Capital surplus	12		-		-12	
Retained earnings	703,036		702,984		-52	
Treasury stock	-35,450		-21,033		+14,416	Impact of making Biofermin Pharmaceutical Co., Ltd. a wholly owned subsidiary
II Accumulated other comprehensive income	31,105	3.5%	35,447	4.0%	+4,341	
Valuation difference on securities	30,026		25,586		-4,439	
Foreign currency translation adjustment	-235		8,488		+8,724	
Remeasurements of defined benefit plans	1,315		1,371		+56	
III Share acquisition rights	801	0.1%	753	0.1%	-48	
IV Non-controlling interests	28,900	3.3%	19,806	2.2%	-9,094	Impact of making Biofermin Pharmaceutical Co., Ltd. a wholly owned subsidiary
Total net assets	758,406	86.5%	767,957	86.5%	+9,550	
Total liabilities and net assets	876,923	100.0%	888,159	100.0%	+11,235	

* Figures were obtained after application of the accounting standard for revenue recognition

Consolidated P/L Statement

(Millions of yen)

	End of FY2020		End of FY2021		change	
	(March 31, 21)	% total	(March 31, 22)	% total		
Net sales	267,920	100.0%	268,203	100.0%	+283	
Cost of sales	104,162	38.9%	104,371	38.9%	+209	
Gross profit on sales	163,757	61.1%	163,831	61.1%	+74	
Provision for sales returns	-57		-		+57	
Gross profit	163,815	61.1%	163,831	61.1%	+16	
Selling, general and administrative expenses	143,849	53.7%	153,088	57.1%	+9,238	
Research and development expenses	20,251		19,366		-884	
Advertising expenses	25,017		31,898		+6,880	
Sales promotion expenses	15,255		14,438		-817	
Personnel expenses	32,953		34,128		+1,174	
Other	50,371		53,257		+2,885	
Operating Profit	19,965	7.5%	10,743	4.0%	-9,221	
Non-operating income	6,483	2.4%	8,478	3.2%	+1,995	
Non-operating expenses	502	0.2%	809	0.3%	+306	
Ordinary Profit	25,946	9.7%	18,412	6.9%	-7,533	
Extraordinary income	24	0.0%	4,119	1.5%	+4,094	FY2021: Sale of investment securities +4,064
Extraordinary losses	2,994	1.1%	1,134	0.4%	-1,860	
Profit before income taxes and minority interests	22,976	8.6%	21,398	8.0%	-1,578	
Income taxes	7,782	2.9%	6,448	2.4%	-1,333	
Profit	15,194	5.7%	14,950	5.6%	-244	
Profit attributable to non-controlling interests	1,878	0.7%	1,828	0.7%	-50	
Profit attributable to owners of parent	13,316	5.0%	13,122	4.9%	-194	

* Figures were obtained after application of the accounting standard for revenue recognition

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2019 (FY2018)	March 2020 (FY2019)	March 2021 (FY2020)	March 2022 (FY2021)	(Est) March 2023 Full year
Self-Medication operations	169,088	209,806	217,056	229,659	243,600
(YOY%)	(-2.4%)	(+24.1%)	(+3.5%)	(+5.8%)	(+6.1%)
Japan	135,579	137,808	122,977	127,904	135,300
Overseas	30,867	69,440	91,697	100,322	106,000
Other	2,642	2,557	2,382	1,433	2,300
Prescription Pharmaceutical operations	74,950	63,371	50,863	38,543	36,900
(YOY%)	(-15.4%)	(-15.4%)	(-19.7%)	(-24.2%)	(-4.3%)
Ethical drugs	72,983	61,894	49,965	36,530	36,400
Other	1,967	1,477	898	2,012	500
Total	244,039	273,178	267,920	268,203	280,500

* Figures were obtained after application of the accounting standard for revenue recognition

Consolidated Operating Profit by Segment

(Millions of yen)

	March 2019 (FY2018)	March 2020 ^{*2} (FY2019)	March 2021 (FY2020)	March 2022 (FY2021)	(Est) March 2023 Full year
Self-Medication operations	30,287	18,694	19,395	14,128	24,500
(YOY%)	(+0.4%)	(-38.3%)	(+3.7%)	(-27.2%)	(+73.4%)
Earnings before the amortization of goodwill and trademarks		27,027	31,438	26,547	36,600
Prescription Pharmaceutical operations (YOY%)	2,685	4,144	2,495	-1,319	-6,500
		(+54.4%)	(-39.8%)	(-)	(-)
Other ^{*1}	-1,760	-1,702	-1,925	-2,065	-2,000
	(-)	(-)	(-)	(-)	(-)
Total	31,211	21,137	19,965	10,743	16,000

* Figures were obtained after application of the accounting standard for revenue recognition

*1 The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

*2 Retroactive revisions to the fiscal year ended March 31, 2021 due to the determination of the allocation of acquisition costs associated with business combinations

Consolidated Sales - Leading Brands of Self-Medication Operations & Sales by Region

(Billions of Yen)

	March 2019 (FY2018)	March 2020 (FY2019)	March 2021 (FY2020)	March 2022		(Est) March 2023	
				(FY2021)	YOY	(FY2022)	YOY
Japan ^{*1}	135.6	137.8	123.0	127.9		135.3	
<i>Lipovitan</i> series ^{*3}	53.2	52.0	46.7	48.8	+4.5%	52.3	+7.2%
<i>Pabron</i> series	28.9	29.8	21.1	21.9	+3.7%	20.6	-6.1%
<i>RiUP</i> series	15.3	14.9	14.9	15.2	+2.5%	14.9	-2.3%
<i>Biofermin</i> series	10.2	10.7	9.8	10.6	+8.1%	11.1	+5.6%
<i>NARON</i> series	3.4	3.4	3.2	3.2	-1.8%	3.7	+18.4%
GI treatment series	3.7	3.7	3.4	3.4	+1.3%	3.4	-1.0%
<i>VICKS</i> series	3.0	3.1	3.0	3.3	+7.9%	3.2	-2.5%
<i>Livita</i> series	3.0	3.2	3.1	3.1	-2.0%	3.1	+0.5%
<i>Colac</i> series	4.0	4.3	3.1	3.2	+2.5%	2.9	-9.0%
Overseas ^{*1}	30.9	69.4	91.7	100.3	+9.4%	106.0	+5.7%
Asia	27.6	42.5	41.6	48.5	+16.4%	52.4	+8.2%
Europe and America	1.9	25.8	49.7	50.7	+2.1%	53.3	+5.1%
Others ^{*1}	2.6	2.6	2.4	1.4	-39.8%	2.3	+60.5%

(Rounded to the nearest hundred-million)

*1 Figures were obtained after application of the accounting standard for revenue recognition

*2 The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

*3 For the *Lipovitan* series, revised figures prior to the fiscal year ended March 31, 2021

to unify the standards for the fiscal year ended March 31, 2022.

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2019 (FY2018)	March 2020 (FY2019)	March 2021 (FY2020)	March 2022		(Est) March 2023	
				(FY2021)	YOY	(FY2022)	YOY
<i>Lipovitan</i> series	53.2	52.0	46.7	48.8	+4.5%	52.3	+7.2%
<i>Lipovitan D</i>	34.5	33.2	29.6	29.9	+1.0%	30.3	+1.3%
Others	18.7	18.8	17.2	18.9	+10.4%	22.1	+16.5%

(Rounded to the nearest hundred-million)

*1 The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

*2 Revised figures prior to the fiscal year ended March 31, 2021 to unify the standards for the fiscal year ended March 31, 2022.

Consolidated Sales - Leading Brands of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 2019 (FY2018)	March 2020 (FY2019)	March 2021 (FY2020)	March 2022		(Est) March 2023	
				(FY2021)	YOY	(FY2022)	YOY
<i>Lusefi</i>	5.6	7.1	10.8	12.4	+14.5%	13.6	+9.9%
<i>Bonviva</i>	6.4	6.6	6.9	7.4	+6.7%	7.1	-3.4%
<i>LOQOA</i>	3.9	3.8	3.4	4.4	+30.3%	4.7	+6.1%
<i>Biofermin</i>	3.5	3.9	3.8	4.1	+6.7%	4.1	+0.9%
<i>Clarith</i>	3.5	3.1	2.4	2.2	-8.6%	1.6	-26.4%
<i>Palux</i>	5.3	4.3	2.2	2.2	+0.4%	1.4	-36.2%
<i>Geninax</i>	3.5	3.9	2.2	0.4	-82.2%	1.2	+206.8%

(Rounded to the nearest hundred-million)

* The sales by major brands reflects the figures before application of the accounting standard for revenue recognition.

Consolidated: Capital Expenditure

(Millions of yen)

	March 2019 (FY2018)	March 2020 (FY2019)	March 2021 (FY2020)	March 2022 (FY2021)	(Est) March 2023 Full year
Total capital expenditure	5,259	9,469	15,121	16,880	34,700
Taisho Pharmaceutical	3,974	6,471	7,793	10,404	19,189
Production department	1,061	1,597	1,379	2,284	1,320
Research department	979	940	1,519	4,900	15,202
Head Office and the others	1,932	3,933	4,894	3,220	2,667
Other subsidiaries	1,285	2,998	7,327	6,476	15,511

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2019 (FY2018)	March 2020 (FY2019)	March 2021 (FY2020)	March 2022 (FY2021)	(Est) March 2023 Full year
Depreciation and amortization	10,073	12,610	14,700	15,379	15,200
Cost of sales	3,225	4,325	5,278	5,573	6,000
SGA expenses	6,847	8,284	9,421	9,805	9,200

Consolidated: R&D Expenses

(Millions of yen)

	March 2019 (FY2018)	March 2020 (FY2019)	March 2021 (FY2020)	March 2022 (FY2021)	(Est) March 2023 Full year
Total R&D expenses	20,801	22,876	20,251	19,366	22,600
Self-Medication operations	5,353	6,754	7,492	7,828	8,600
Prescription Pharmaceutical operations	15,447	16,121	12,758	11,538	14,000

Major Subsidiaries and Affiliates

(As of March 31, 2022)

Company	Address	Capital	Business	Ownership ^{*1}
(1) Consolidated subsidiaries				
Taisho Pharmaceutical Co., Ltd.	Tokyo, Japan	,000 Yen 29,837,892	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co., Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co., Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co., Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	100.0 ^{*2}
Taisho Pharma Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	PD	100.0
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co., Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co., Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co., Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 10,000	SMG	100.0
Osotspha Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 S\$ 1,365	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 1,307,460,710	SMG	51.0
UPSA SAS	France	,000 EUR 852,103	SMG	100.0
UPSA Switzerland A.G.	Switzerland	,000 CHF 1,000	SMG	100.0
UPSA Italy S.r.l.	Italia	,000 EUR 10	SMG	100.0
UPSA Belgium S.A.	Belgium	,000 EUR 62	SMG	100.0
(2) Equity accounting method				
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.0

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*1 Ownership: including the portion of indirect ownership

*2 Shares were exchanged to become a subsidiary fully owned by Taisho Pharmaceutical Holdings Co., Ltd. on July 30, 2021.

Shareholders Information (as of end of March 2022)

Major Shareholders

(Thousands of Shares)

Shareholders	Number of shares	% of total
The Uehara Memorial Foundation	15,000	18.28%
Shoji Uehara	7,707	9.39%
The Master Trust Bank of Japan, Ltd. (Trust account)	6,531	7.96%
Uehara Museum	3,900	4.75%
Sumitomo Mitsui Banking Corp.	3,000	3.66%
MUFG Bank, Ltd.	3,000	3.66%
Akira Uehara	2,143	2.61%
Kajima Corporation	1,650	2.01%
Custody Bank of Japan, Ltd. (Trust account)	1,648	2.01%
Custody Bank of Japan, Ltd. (Sumitomo Mitsui Trust Bank, Limited Retruster Account/ Sumitomo Chemical Company, Limited Employee Pension Trust Account)	1,530	1.86%

Shares less than one thousand are rounded down.

Treasury stock of 3,085 thousand shares are excluded from the above as these shares do not have voting rights.

The shareholding ratio is calculated excluding treasury stock. (Rounded to the nearest second decimal place)

Distribution of Ownership Among Shareholders

	% of total
Financial Institutions	21.93%
Financial Instruments Firms	0.56%
Other companies	36.58%
Foreign Companies	14.65%
Individuals and Others	26.28%
Total	100.00%

The shareholder composition is calculated excluding treasury stock of 3,085 thousand shares.

(Rounded to the nearest second decimal place)

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 13 , 2022

In Japan

Approved

Lusefi (Oral)

< Application	> Type2 diabetes
< Development	> In-house
< Description	> SGLT2 (Sodium-Glucose Cotransporter2) inhibitor
< Remarks	> Generic name: Luseogliflozin Hydrate Product name: Lusefi Orally disintegrating film drug (drug form added)

Filed

TS-152 (Injection)

< Application	> Articular rheumatism against which existing therapies have insufficient efficacy
< Development	> In-license (Licensor: Ablynx)
< Description	> Anti-TNF(Tumor Necrosis Factor)- α antibody
< Remarks	> Generic name: Ozoralizumab (Genetical Recombination)

Phase 3

TS-071(Oral)

< Application	> Type2 diabetes (Pediatric)
< Development	> In-house
< Description	> SGLT2 (Sodium-Glucose Cotransporter2) inhibitor
< Remarks	> Generic name: Luseogliflozin Hydrate Product name: Lusefi

Phase 2

TS-142 (Oral)

< Application	> Insomnia
< Development	> In-house

Phase 1

TS-172 (Oral)

< Application	> Hyperphosphatemia
< Development	> In-house

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 13 , 2022

Overseas

Phase 2

TS-161 (Oral)

< Target disease > Depression

< In-house/Licensed-in > In-house

Phase 1

TS-134 (Oral)

< Target disease > Schizophrenia

< In-house/Licensed-in > In-house

TS-142 (Oral)

< Target disease > Insomnia

< In-house/Licensed-in > In-house

Launch of New Products

As of May 13, 2022

New Products Since FY2021 3Q Earnings Announcement (February 1, 2022)

Self-Medication Operations

RIUP ENERGY PROTECT SHAMPOO STRONG OILY

RIUP ENERGY PROTECT SHAMPOO OILY

RIUP ENERGY PROTECT SHAMPOO DRY

RIUP ENERGY PROTECT PACK CONDITIONER

< Description > The medicated scalp care item series characterized by aggressive cleansing that washes out greasy scalp sebum containing large amounts of triglyceride are intended for men who worry about the future of their scalp and hair. Ensures long-lasting fine foaming due to its original formulation. Three shampoo products cleanse greasy scalp sebum thoroughly, and a conditioner softens and moisturizes the scalp after the aggressive cleansing of sebum.

< Launch > February 2022

TAISHO Euglena

< Description > Contains three types of superfood manufactured by Euglena Co., Ltd.: Ishigaki Island Euglena from Ishigaki Island, Yaeyama Chlorella, and Spirulina. The supplement facilitates nutritional supplementation, containing 92 nutrients including vitamins, minerals, amino acids, and unsaturated fatty acids.

< Launch > March 2022

PABRON Protect Mask Regular Size

< Description > The JIS-conforming^{*1} product employs a special antistatic filter providing superior protection, blocking 99% of droplets containing viruses/bacteria, pollen, and microparticles. Ensures high adhesion with a long nose bar and a side-adhesion design while the mouth area spacing bar and the four-fold pleating prevent the mask from adhering to the mouth. The mask emphasizes comfort to facilitate breathing and talking.

^{*1} The official standard for standardizing performance and testing methods of facial masks to allow consumers to choose and wear a mask with security (JIS T 9001).

< Launch > April 2022

Premiumcare powder stick

< Description > This food with functional claims (powdery green tea) is recommended for people who are concerned about health checkup items such as high blood pressure, postprandial blood glucose levels, and postprandial neutral fat levels. It has been reported that piperine derived from long pepper improved blood pressure in people with higher blood pressure^{*2} and helped maintain normal blood pressure, and digestion-resistant dextrin suppressed the increase of postprandial blood glucose levels and postprandial blood neutral fat levels and improved conditioned the bowel condition.

^{*2} 130-139 mmHg of systolic arterial pressure or 85-89 mmHg of diastolic blood pressure

< Launch > April 2022

Launch of New Products

As of May 13, 2022

New Products Since FY2021 3Q Earnings Announcement (February 1, 2022)

Self-Medication Operations

LipovitanDX Amino

< Description > The vitamin-based health agent contains nutrients such as taurine, a vitamin B complex (B₁, B₂, and B₆), BCAA^{*3} and calcium hydrogen phosphate. Taurine and the vitamin B complex are a part of the energy cycle, helping the body recover from fatigue. BCAA^{*3} acts in the synthesis of muscle protein to help restore reduced muscular power that becomes more obvious with age.

^{*3} Branched-chain amino acids L-valine, L-leucine and L-isoleucine

< Launch > April 2022

Lipovitan Gold V Royal

< Description > Packed in a small bottle, the beverage is a designated quasi-drug that contains 14 rich ingredients including taurine, royal jelly, goji berries and Solomon's seal (the last two are herbal medicines for nutritional fortification).

< Launch > April 2022

THE MYTOL ESSENCE

< Description > The booster serum makes the skin beautiful, firm and translucent.^{*4} The active ingredient niacinamide improves wrinkles, suppresses melanin production and prevents dark spots and freckles. ^{*4} The stratum corneum

< Launch > April 2022

Lipovitan water

< Description > This nutritional supplementary food contains citric acids and arginine which are sources of energy in addition to the recommended daily intake^{*5} of vitamins B₁, B₂ and B₆. Dissolve the product which is in a powder form in water before consumption. Recommended for the prevention of heat stroke when doing sports or working outdoors, including salt in the quantity necessary for the prevention of heat stroke specified in the guidelines for labeling with heat stroke countermeasure claims published by the Japan Soft Drink Association.^{*6}

^{*5} Dietary intake in Japanese people aged 15 or older (2020) ^{*6} Contains 0.1 g/100 ml salt when dissolved in 500 ml water. Conforms to the guidelines for labeling with heat stroke countermeasure claims published by the Japan Soft Drink Association.

< Launch > April 2022

Launch of New Products

As of May 13, 2022

New Products Since FY2021 3Q Earnings Announcement (February 1, 2022)

Self-Medication Operations

Lipovitan Kids Jelly mixfruit flavor (no juice)

Lipovitan Kids Jelly yoghurt flavor

< Description > A refreshing beverage (jelly type) containing vitamins B₁, B₂, B₆ and calcium, which are essential nutrients for growing children. Two flavors have been released in addition to strawberry and grape (both contain no fruit juice): mixed fruit (contains no fruit juice) and yogurt (contains lactobacillus).

< Launch > April 2022

CLINILABO HEPARIO CREAM

CLINILABO HEPARIO LOTION

CLINILABO HEPARIO MOIST BARRIER

< Description > As dry skin therapies, CLINILABO HEPARIO CREAM and CLINILABO HEPARIO LOTION restore chapped skin tissue damaged by drying with three active ingredients: heparinoid (moisturizing), allantoin (skin repair), and tocopheryl acetate (blood circulation promotion). The medicated hand cream CLINILABO HEPARIO MOIST BARRIER moisturizes dry hand skin and prevents rough skin with two active ingredients: heparinoid (moisturizing ingredient) and dipotassium glycyrrhizinate (rough skin preventing ingredient).

< Launch > April 2022

TAISHO Locofull

< Description > Three tablets, the recommended daily intake, contain 500 mg N-acetylglucosamine and 7.2 mg polymethoxyflavone derived from black ginger. They are ingredients with specific health-related functions. We recommend you take three tablets a day to be joyful, stay active and walk powerfully. The food is suitable for middle-aged to elderly people who want to take care of knee joints and muscular leg strength.

< Launch > April 2022
